FMNL1 Exhibits Pro-Metastatic Activity via CXCR2 in Clear Cell Renal Cell Carcinoma

Mei-Fang Zhang,Qiu-Li Li,Yu-Feng Yang,Yun Cao,Chris Zhiyi Zhang
DOI: https://doi.org/10.3389/fonc.2020.564614
IF: 4.7
2020-11-26
Frontiers in Oncology
Abstract:Formin-like (FMNL) proteins are responsible for cytoskeletal remodeling and have been implicated in the progression and spread of human cancers. Yet the clinical significance and biological function of FMNL1 in clear cell renal cell carcinoma (ccRCC) remain unclear. In this study, the expression of FMNL1 in ccRCC and its clinical value were determined by tissue microarray-based IHC and statistical analyses. The role of FMNL1 in ccRCC metastasis and the underlying mechanism were investigated via in vitro and in vivo models using gene regulation detection, ChIP, Luciferase reporter assays, and rescue experiments. We show that FMNL1 is upregulated in ccRCC and exhibits pro-metastatic activity via induction of CXCR2. High expression of FMNL1 is significantly correlated with advanced tumor stage, higher pathological tumor grade, tumor metastasis, and unfavorable prognosis in two independent cohorts containing over 800 patients with ccRCC. The upregulation of FMNL1 in ccRCC is mediated by the loss of GATA3. Ectopic expression of FMNL1 promotes, whereas FMNL1 depletion inhibits cell migration in vitro and tumor metastasis in vivo . The FMNL1-enhanced cell mobility is markedly attenuated by the knockdown of CXCR2. Further studies demonstrate that FMNL1 increases the expression of CXCR2 via HDAC1. In clinical samples, FMNL1 expression is positively associated with CXCR2, and is negatively connected to GATA3 expression. Collectively, our data suggest FMNL1 serve as a potential prognostic factor and function as an oncogene. The axis of GATA3/FMNL1/CXCR2 may present a promising therapeutic target for tumor metastasis in ccRCC.
oncology
What problem does this paper attempt to address?
Based on the provided text content, the problems that this paper attempts to solve can be summarized as follows: The paper mainly explores the role of Formin - like protein 1 (FMNL1) in clear cell renal cell carcinoma (ccRCC) and its underlying mechanisms. Specifically, the research aims to answer the following key questions: 1. **Expression of FMNL1 in ccRCC**: Is the expression of FMNL1 increased in ccRCC tissues? What is the relationship between this increase and the clinical prognosis of patients? 2. **Functional role of FMNL1**: Does FMNL1 play a pro - metastatic role in ccRCC cell migration and tumor metastasis? What are the specific mechanisms? 3. **Regulatory mechanism of FMNL1**: What factors cause the high expression of FMNL1 in ccRCC? In particular, what is the role of GATA3 in it? 4. **Relationship between FMNL1 and CXCR2**: How does FMNL1 promote tumor metastasis by regulating the expression of CXCR2? Is HDAC1 involved in this process? ### Main findings - **High expression of FMNL1 in ccRCC**: The study found that the expression of FMNL1 in ccRCC tissues was significantly higher than that in non - tumor tissues, and high expression was significantly associated with advanced tumor stage, higher pathological grade, tumor metastasis and poor prognosis. - **Pro - metastatic role of FMNL1**: Both in vitro experiments and in vivo models showed that overexpression of FMNL1 promoted cell migration and tumor metastasis, while knockdown of FMNL1 inhibited these processes. - **Regulation of FMNL1 by GATA3**: The deletion of GATA3 led to high expression of FMNL1, indicating that GATA3 may negatively regulate the expression of FMNL1 through an indirect mechanism. - **FMNL1 promotes metastasis through CXCR2**: FMNL1 promotes epithelial - mesenchymal transition (EMT) by up - regulating the expression of CXCR2, thereby enhancing cell migration and tumor metastasis. This process depends on the participation of HDAC1. ### Conclusion In summary, this paper reveals the high expression of FMNL1 in ccRCC and its mechanism of promoting tumor metastasis through CXCR2. The research results suggest that FMNL1 may be a potential prognostic marker and therapeutic target, especially in the intervention of the GATA3/FMNL1/CXCR2 axis.